Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis

NeuroMolecular Medicine

Volumn 12, Issue 3, 2010, Pages 217-223

  Martínez, Carmen ^a   García Martín, Elena ^a   Benito León, Julián ^b   Calleja, Patricia ^b   Díaz Sánchez, Maria ^b   Pisa, Diana ^c   Alonso Navarro, Hortensia ^d,e   Ayuso Peralta, Lucía ^d   Torrecilla, Dolores ^d   Agúndez, José A G ^a   Jiménez Jiménez, Félix Javier ^d,f  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^f Hospital Universitario del Sureste de Madrid   (Spain)

Author keywords

Genetic polymorphisms; Genetics; Multiple sclerosis; Oxidative stress; Paraoxonase 1; Risk factors

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR;

ADULT; ARYLDIALKYLPHOSPHATASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 78649935311     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12017-009-8095-9     Document Type: Article

References (57)

1. Adkins, S., Gan, K. N., Mody, M., & La Du, B. N. (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. American Journal of Human Genetics, 52, 598-608.
2. Akhmedova, S., Anisimov, S., Yakimovsky, A., & Schwartz, E. (1999). Gln → Arg 191 polymorphism of paraoxonase and Parkinson's disease. Human Heredity, 49, 178-180.
3. Akhmedova, S. N., Yakimovsky, A. K., & Schwartz, E. I. (2001). Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. Journal of the Neurological Sciences, 184, 179-182.
4. Amorini, A. M., Petzold, A., Tavazzi, B., Eikelenboom, J., Keir, G., Belli, A., et al. (2009). Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clinical Biochemistry, 42, 1001-1006.
5. Bizzozero, O. A., DeJesus, G., Callahan, K., & Pastuszyn, A. (2005). Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. Journal ofNeuroscience Research, 81 , 687-695. (Pubitemid 41532164)
6. Bulpitt, C. J. (1987). Confidence intervals. Lancet, 1, 494-497.
7. Calabrese, V., Raffaele, R., Cosentino, E., & Rizza, V. (1994). Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. International Journal of Clinical Pharmacology Research, 14, 119-123.
8. Can Demirdöǧen, B., Türkanoǧlu, A., Bek, S., Sanisoǧlu, Y., Demirkaya, S., Vural, O., et al. (2008). Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clinical Biochemistry, 41, 1-9.
9. Carmine, A., Buervenich, S., Sydow, O., Anvret, M., & Olson, L. (2002). Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Movement Disorders, 17, 764-766.
10. Clarimon, J., Eerola, J., Hellstrom, O., Tienari, P. J., & Singleton, A. (2004). Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. Neuroscience Letters, 367, 168-170.
11. Cowan, J., Sinton, C. M., Varley, A. W., Wians, F. H., Haley, R. W., & Munford, R. S. (2001). Gene therapy to prevent organophosphate intoxication. Toxicology and Applied Pharmacology, 173, 1-6.
12. Dantoine, T. F., Drouet, M., Debord, J., Merle, L., Cogne, M., & Charmes, J. P. (2002). Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Annals of the New York Academy of Sciences, 977, 239-244.
13. de Bustos, F., Navarro, J. A., de Andrés, C., Molina, J. A., Jiménez-Jiménez, F. J., Ortí-Pareja, M., et al. (1999). Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. European Neurology, 41, 44-47. (Pubitemid 29043111)
14. Diekstra, F. P., Beleza-Meireles, A., Leigh, N. P., Shaw, C. E., & Al-Chalabi, A. (2009). Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport, 20, 186-190.
15. Duric, G., Svetel, M., Nikolaevic, S. I., Dragadevic, N., Gavrilovic, J., & Kostic, V. S. (2007). Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease. Vojnosanitetski Pregled, 64, 25-30.
16. Dyment, D. A., Ebers, G. C., & Sadovnick, A. D. (2004). Genetics of multiple sclerosis. Lancet Neurology, 3, 104-110.
17. Erlich, P. M., Lunetta, K. L., Cupples, L. A., Huyck, M., Green, R. C., Baldwin, C. T., et al. (2006). Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Human Molecular Genetics, 15, 77-85.
18. Ferretti, G., Bacchetti, T., Principi, F., Di Ludovico, F., Viti, B., Angeleri, V. A., et al. (2005). Increased levels of lipid hydroperoxydes in plasma of patients with multiple sclerosis: A relationship with paraoxonase activity. Multiple Sclerosis, 11, 677-682.
19. Fong, C. S., Cheng, C. W., & Wu, R. M. (2005). Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurologica (Taiwan), 14, 55-60.
20. Giordano, M., D'Alfonso, S., & Momigliano-Richiardi, P. (2002). Genetics of multiple sclerosis: linkage and association studies. American Journal of Pharmacogenomics, 2, 37-58.
21. Greco, A., Minghetti, L., Puopolo, M., Cannoni, S., Romano, S., Pozzilli, C., et al. (2004). Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 224, 23-27.
22. Hadjigeorgiou, G. M., Malizos, K., Dardiotis, E., Aggelakis, K., Dardioti, M., Zibis, A., et al. (2007). Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. Journal of Orthopaedic Research, 25, 1087-1093.
23. Helbecque, N., Cottel, D., Codron, V., Berr, C., & Amouyel, P. (2004). Paraoxonase 1 gene polymorphisms and dementia in humans. Neuroscience Letters, 358, 41-44.
24. Huang, Q., Liu, Y. H., Yang, Q. D., Xiao, B., Ge, L., Zhang, N., et al. (2006). Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurological Research, 28, 549-554.
25. Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J., & Furlong, C. E. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics, 3, 73-76.
26. Jiménez-Jiménez, F. J., de Bustos, F., Molina, J. A., de Andrés, C., Gasalla, T., Ortí-Pareja, M., et al. (1998). Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neuroscience Letters, 249, 65-67. (Pubitemid 28308235)
27. Kalousová, M., Havrdová, E., Mrázová, K., Spacek, P., Braun, M., Uhrová, J., et al. (2005). Advanced glycoxidation end products in patients with multiple sclerosis. Prague Medical Report, 106, 167-174.
28. Kastenbauer, S., Kieseier, B. C., & Becker, B. F. (2005). No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis. Journal of Neurology, 252, 611-612.
29. Kelada, S. N., Costa-Mallén, P., Checkoway, H., Viernes, H. A., Farin, F. M., Smith-Weller, T., et al. (2003). Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 74, 545-548.
30. Kondo, I., & Yamamoto, M. (1998). Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Research, 806, 271-273.
31. Kucukali, C. I., Aydin, M., Ozkok, E., Orhan, N., Cakir, U., Kilic, G., et al. (2008). Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population. Psychiatric Genetics, 18, 289-294.
32. La Du, B. N. (1992). Human serum paraoxonase/arylesterase. In W. Kalow (Ed.), Pharmacogenetics of drugs metabolism (pp. 51-91). New York: Pergamon Press.
33. Langemann, H., Kabiersch, A., & Newcombe, J. (1992). Measurement of low molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. European Neurology, 32, 248-252.
34. Leduc, V., & Poirier, J. (2008). Polymorphisms at the paraoxonase 1 L55 M and Q192R loci affect the pathophysiology of Alzheimer's disease: Emphasis on the cholinergic system and beta-amyloid levels. Neurodegeneration Diseases, 5, 225-227.
35. LeVine, S. M. (1992). The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Medical Hypotheses, 39, 271-274.
36. Li, H. L., Liu, D. P., & Liang, C. C. (2003). Paraoxonase gene polymorphisms, oxidative stress, and diseases. Journal of Molecular Medicine, 81, 766-779.
37. Mackness, B., Durrington, P. N., & Mackness, M. I. (2002). The paraoxonase gene family and coronary heart disease. Current Opinion in Lipidology, 13, 357-362.
38. Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Julier, K., Abuasha, B., et al. (1998). Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis, 139, 341-349.
39. Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W., & Hegele, R. A. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Current Opinion in Lipidology, 7, 69-76.
40. Mattsson, N., Haghighi, S., Andersen, O., Yao, Y., Rosengren, L., Blennow, K., et al. (2007). Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neuroscience Letters, 414, 233-236.
41. McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Härtung, H. P., Lublin, F. B., et al. (2001). Recommended diagnostic criteria for multiple sclerosis guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50, 121-127.
42. Newcombe, J., Li, H., & Cuzner, M. L. (1994). Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: Implications for pathogenesis. Neuropathology and Applied Neurobiology, 20, 152-162.
43. Pertegas-Diaz, S., & Pita-Fernández, S. (2003). Calculo del poder estadístico de un estudio. Cadernos de Atención Primaria, 10, 59-63.
44. Pugliatti, M., Harbo, H. F., Holmøy, T., Kampman, M. T., Myhr, K. M., Riise, T., et al. (2008). Environmental risk factors in multiple sclerosis. Acta Neurologica Scandinavica Supplement, 188, 34-40.
45. Ramagopalan, S. V., Deluca, G. C., Degenhardt, A., & Ebers, G. C. (2008). The genetics of clinical outcome in multiple sclerosis. Journal of Neuroimmunology, 201-202, 183-199.
46. Schmidt, R., Schmidt, H., Fazekas, F., Kapeller, P., Roob, G., Lechner, A., et al. (2000). MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: Three-year follow-up of the austrian stroke prevention study. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1811-1816.
47. Shin, B. S., Oh, S. Y., Kim, Y. S., & Kim, K. W. (2008). The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurologica Scandinavica, 117, 237-243.
48. Sidoti, A., Antognelli, C., Rinaldi, C., D'Angelo, R., Dattola, V., Girlanda, P., et al. (2007). Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Multiple Sclerosis, 13, 446-153.
49. Taylor, M. C., Le Couteur, D. G., Mekkick, G. D., & Board, P. G. (2000). Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. Journal of Neural Transmission, 107, 979-983.
50. Toshniwal, P. K., & Zarling, E. J. (1992). Evidence for increased lipid peroxidation in multiple sclerosis. Neurochemical Research, 17, 205-207.
51. Ueno, T., Shimazaki, E., Matsumoto, T., Watanabe, H., Tsunemi, A., Takahashi, Y., et al. (2003). Paraoxonase 1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Medical Science Monitor, 9, CR208-212.
52. van Horssen, J., Schreibelt, G., Bö, L., Montagne, L., Drukarch, B., van Muiswinkel, F. L., et al. (2006). NAD(P)H:quinone oxido-reductase 1 expression in multiple sclerosis lesions. Free Radical Biology and Medicine, 41, 311-317. (Pubitemid 43928505)
53. van Horssen, J., Schreibelt, G., Drexhage, J., Hazes, T., Dijkstra, C. D., van der Valk, P., et al. (2008). Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biology and Medicine, 45, 1729-1737.
54. Wang, J., & Liu, Z. (2000). No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. Movement Disorders, 15, 1265-1267.
55. Wills, A. M., Cronin, S., Slowik, A., Kasperaviciute, D., Van Es, M. A., Morahan, J. M., et al. (2009). A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology, 73, 16-24.
56. Zintzaras, E., & Hadjigeorgiou, G. M. (2004). Association of parao-xonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis. Journal of Human Genetics, 49, 474-481.
57. Zuliani, G., Ble', A., Zanca, R., Munari, M. R., Zurlo, A., Vavalle, C., et al. (2001). Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. Acta Neurologica Scandinavica, 103, 304-308. (Pubitemid 32368006)